Arrayit (OTCMKTS:ARYC) and BioNano Genomics (NASDAQ:BNGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Risk and Volatility
Arrayit has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, BioNano Genomics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Arrayit and BioNano Genomics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioNano Genomics has a consensus price target of $3.00, indicating a potential upside of 188.46%. Given BioNano Genomics’ higher possible upside, analysts clearly believe BioNano Genomics is more favorable than Arrayit.
Earnings and Valuation
This table compares Arrayit and BioNano Genomics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioNano Genomics||$12.00 million||2.30||-$18.50 million||($2.61)||-0.40|
Arrayit has higher earnings, but lower revenue than BioNano Genomics.
Institutional and Insider Ownership
5.2% of BioNano Genomics shares are owned by institutional investors. 58.0% of Arrayit shares are owned by insiders. Comparatively, 56.7% of BioNano Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Arrayit and BioNano Genomics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BioNano Genomics beats Arrayit on 5 of the 9 factors compared between the two stocks.
Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.
About BioNano Genomics
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Receive News & Ratings for Arrayit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrayit and related companies with MarketBeat.com's FREE daily email newsletter.